The FDA’s December 2025 expert panel signals a major shift in how testosterone decline, aging, and treatment access are viewed in men’s health.
The FDA’s December 2025 expert panel signals a major shift in how testosterone decline, aging, and treatment access are viewed in men’s health.
A significant change in the perception of aging, testosterone reduction, and therapy access in men’s health is indicated by the FDA’s December 2025 expert panel.